Gland Pharma IPO Detail

Business Overview

Gland Pharma established in Hyderabad, 1978 is one of the fastest growing generic injectables-focused companies by revenue in the United States from 2014 to 2019 (Source: IQVIA Report).

As on March 31, 2020 they sell their products in over 60 countries which includes USA, Europe, Canada, Australia etc.

One of their Promoters, Shanghai Fosun Pharma, is a global pharmaceutical major.

They are present in sterile injectables, oncology and ophthalmics, and focus on complex injectables, NCE-1s, First-to-File products and 505(b)(2) filings. Their delivery systems include liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops.

They have 7 manufacturing facilities in India, comprising four finished formulations facilities with a total of 22 production lines and three API facilities.

As of March 31, 2020, they along with their partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval.

In Fiscal Year 2020, Out of the total revenue 66.74% comes from USA and 17.74% from India.

Their total revenue from operations has grown at a CAGR of 27.38% from Fiscals 2018 to 2020. Our EBITDA has grown at a CAGR of 36.90% from Fiscals 2018 to 2020.

Company Strengths

• Diversified B2B Model
• Internal R&D and regulatory capabilities
• Extensive Manufacturing Capabilities
• Strong Growth track record with healthy cash flows

Promoters

Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd are the company promoters.